Cancer heterogeneity, plasticity and resistance to therapies
The main goal of the research unit is to better understand the mechanisms of resistance to cancer treatments. Using molecular and cell biology strategies, genetics, animal models and hospital biological resources, we investigate molecular mechanisms of resistance in solid tumors and hematologic malignancies and develop new diagnostic, prognostic and predictive markers for precision medicine. CANTHER is composed of 5 teams with specific and complementary expertises, competences and skill. We benefit from an outstanding scientific and technologic environment, and develop a pre-clinical and clinical research in close collaboration with clinicians. We are open to all academic and industrial collaborations and propose services in line with our expertise.
Informations
Direction : Isabelle Van Seuningen
http://canther.fr/
https://twitter.com/canther_lille
1, place de Verdun, Bâtiment Cancer
Campus Santé, Université de Lille
59045 LILLE
Mots-clés
cancer, therapy, resistance, dormancy, solid tumors, hematologic malignancies, senescence, fibrosis, stem cells, epigeneticsLocalisation
- Resistance to anti-tumor targeted therapies
- Resistance to chemotherapy
- Resistance associated with the metastatic process
- Markers of resistance
- Senescence and fibrosis associated with resistance
- Mucins and cancer
- Cell plasticity and cancer
- Persistance of leukemic cells
- Tumor dormancy
- Screening of active compounds
- Validation of cancer models for specific studies
- Establishment of chemoresistant tumor models
Our unit is equipped with:
- cell culture rooms, BSL 2 and 3
- microscopes (electron, confocal, light sheet, fluorescent)
- qPCR and digital PCR machines
- flow cytometer
- microfluidic system to study the metastatic process
- IncuCyte live cell analysis system
- ultracentrifuge
- all the basic equipment (cell culture equipment, cell and molecular biology, etc.)